TheraRadar
Clinical-Stage Companies / Foresee Pharmaceuticals

Foresee Pharmaceuticals

Pre-Approval PRO BETA
15
Total Trials
7
Phase 3
5
Phase 2
2
Recruiting
175
Score

Pipeline by Phase

Phase 3
7
Phase 2
5
Phase 1
5

Therapeutic Focus

Healthy Prostatic Neoplasms Prostate Cancer Asthma (Diagnosis) Pulmonary Function

Clinical Trials (15)

NCT05493709 Phase 3 ACTIVE NOT RECRUITING

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Started: 6/2/2023

NCT06795178 Phase 3 WITHDRAWN

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

Started: 7/1/2025

NCT06795191 Phase 3 WITHDRAWN

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer

Started: 6/1/2025

NCT03261999 Phase 3 COMPLETED

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Started: 9/26/2017

NCT02712320 Phase 3 COMPLETED

Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Started: 2/1/2016

NCT02234115 Phase 3 COMPLETED

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Started: 8/1/2014

NCT06475781 Phase 2 RECRUITING

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD

Started: 3/1/2025

NCT07191535 Phase 2 NOT YET RECRUITING

Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)

Started: 1/1/2026

NCT03858686 Phase 2 COMPLETED

The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.

Started: 7/2/2018

NCT04750278 Phase 2 TERMINATED

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Started: 4/6/2021

NCT04522375 Phase 1 WITHDRAWN

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Started: 6/30/2023

NCT06334211 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

Started: 4/16/2024

NCT02238834 Phase 1 COMPLETED

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Started: 6/1/2015

NCT03686930 Phase 1 COMPLETED

Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045

Started: 2/22/2018

NCT03304964 Phase 1 COMPLETED

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Started: 7/21/2017

Drug Candidates

linvemastat Placebo Mirivadelgat placebo Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide FP-014 Triptorelin Mesylate FP-045 FP-020 FP-025 capsules
Activity Status: Active
Last Trial Started: 1/1/2026
Last Trial Ended: 9/20/2024
Trials (12 months): 3
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.